Supplementary materials

COVID-19 pandemic in Saint Petersburg, Russia: combining surveillance and population-based serological study data in May, 2020–April, 2021

Anton Barchuk, Dmitriy Skougarevskiy, Alexei Kouprianov, Daniil Shirokov, Olga Dudkina, Rustam Tursun-zade, Mariia Sergeeva, Varvara Tychkova, Andrey Komissarov, Alena Zheltukhina, Dmitry Lioznov, Artur Isaev, Ekaterina Pomerantseva, Svetlana Zhikrivetskaya, Yana Sofronova, Konstantin Blagodatskikh, Kirill Titaev, Lubov Barabanova, Daria Danilenko

Data appendix

The federal government and St. Petersburg city government made most of the detailed statistics regarding COVID-19 available. However the data are scattered across different sources. The number of daily new cases was obtained from the official federal government website (stopcoronavirus.rf, https://xn--80aesfpebagmfblc0a.xn--p1ai/). The daily reports of new cases were also provided by the St. Petersburg city government and the city Health Committee. While the official website provided a somewhat smoothed pandemic curve, the St. Petersburg city government and Health Committee data looked closer to sources from other countries, with seasonal fluctuations on weekends and holidays. However, the city data are available only from early December 2020. The number of COVID-19 deaths was obtained from the official data from stopcoronavirus.rf. The number of excess deaths was obtained from Kobak (2020), the calculation was based on monthly data from the Federal State Statistics Service of Russia on deaths from any causes [11]. This data is constructed by subtracting the linear trend in monthly deaths over 2015–19 from the monthly deaths data in 2020–21 and is available online https://github.com/dkobak/excess-mortality. We obtained the number of tests to detect SARS-CoV-2 from the official St. Petersburg city government Telegram channel https://t.me/koronavirusspb. The number of hospital admissions are extracted from the St. Petersburg city government and Health Committee reports. The ongoing surveillance for SARS-CoV-2 VOCs in St. Petersburg is carried out by the Smorodintsev Research Institute of Influenza and is described in detail elsewhere [18].

Statistical appendix: estimating the IR and IFR with the Bayesian evidence synthesis model

Observables We conduct K cross-sections of serosurvey of adult population of St. Petersburg, Russia. In each cross-section $k=1,\ldots,K$ we randomly select T_k individuals to get tested out of P_k individuals at risk of infection in the city. Out of those tested we identify CC_k seropositive individuals with confirmed cases of SARS-CoV-2. In each cross-section k we also observe the cumulative number of deaths D_k attributed to COVID-19 since the pandemic onset in the city.

Latent variables We need to make inference on following variables:

- C_k the cumulative total number of infected individuals by wave k,
- IR_k the true infection rate (proportion of population which has been infected by cross-section k), which is the expected value $E[C_k/P_k]$,
- IFR_k the true underlying infection fatality rate, which is the expected value $E[D_k/C_k|C_k]$.

To estimate the IFR across the study cross-sections we closely follow [19] who proposed a simple framework for Bayesian evidence synthesis.

Distributional and modeling assumptions We make the following assumptions on the distribution of the latent variables:

$$CC_k \sim \text{Binomial}\left(T_k, C_k/P_k\right),$$

$$C_k \sim \text{Binomial}\left(P_k, IR_k\right),$$

$$D_k|C_k \sim \text{Binomial}\left(C_k, IFR_k\right).$$

Following [19], to improve the MCMC mixing we replace the assumption for CC_k with $CC_k \sim \text{Binomial}(T_k, IFR_k)$. Then we can replace the conditional assumption $D_k|C_k$ with the unconditional

$$D_k \sim \text{Binomial}(P_k, IFR_k \times IR_k)$$
.

Next we assume that per-cross-section IFR_k and IR_k are distributed according to a random effects model:

$$g(IFR_k) \sim \mathcal{N}(\theta, \tau^2),$$

 $g(IR_k) \sim \mathcal{N}(\beta, \sigma^2),$

where $g(\bullet) \equiv \log(-\log(1-\bullet))$ is the complimentary log-log link function, θ is the mean clog-log-transformed infection fatality rate across the study cross-sections, τ reflects the variability in between-cross-section IFR estimates, β is the mean clog-log-transformed infection rate across the cross-sections, σ captures the variability in between-cross-section IR estimates.

Prior elicitation Following [19, 26] we consider two sets of priors on model parameters:

- Weakly informative priors: $g^{-1}(\theta) \sim \text{Beta}(0.3,30), g^{-1}(\beta) \sim \text{Beta}(1,30), \sigma \sim \text{half-}\mathcal{N}(0,10), \tau \sim \text{half-}\mathcal{N}(0,10);$
- Non-informative flat priors: $g^{-1}(\theta) \sim \text{Uniform}(0,1), \ g^{-1}(\beta) \sim \text{Uniform}(0,1), \ \sigma \sim \text{half-}\mathcal{N}(0,100), \ \tau \sim \text{half-}\mathcal{N}(0,100).$

Estimation and inference The model is fit with JAGS [27] with 5 independent chains, each with 2 million draws (20% burnin, thinning of 100). We then report the median estimates of per-cross-section IFR_k and IR_k and their 95% highest probability density credible intervals [28].

Data To fit the model we need to acknowledge multiple data constraints. For P_k we assume that the entire adult (≥ 18 years old) population of the city is at risk of infection (in a sensitivity analysis we consider the entire city population instead). For cross-sections one and two we take the adult city population count as of January 1, 2020 from the Federal State Statistics Service of Russia*, 4 451 025 individuals. The data on the adult population as of January 1, 2021 is not available at the time of writing of this paper. However, the official data on the total city population is available and amounts to 5 384 342 people as of January 1,

^{*}https://gks.ru/bgd/regl/b20_111/Main.htm †https://petrostat.gks.ru/folder/27595

2021 and 5 398 064 as of January 1, 2020. We assume that the adult population followed the same trend as the total population (a -0.25% decline) in 2020 and assume $P_k=4$ 451 $025\times(1-0.0025)=4$ 439 897 individuals for cross-sections three and four.

We do not take the values T_k and CC_k directly from the per-cross-section test data. To arrive at the seroprevalence estimate in our study we adjusted those naïve figures for test performance and non-response bias. Instead of using the raw counts we invert the reported 95% CI for the seroprevalence estimate for cross-section k. Using a beta prior on the probability of success for a binomial distribution, we can determine a two-sided confidence interval from a beta posterior for any given T_k and CC_k . We define the values of T_k and CC_k that correspond to the reported seroprevalence 95% CI for ELISA Coronapass from Table 1 adjusted for non-response and test characteristics as the effective $T_k^{effective}$ and $CC_k^{effective}$ and use those values in the model. Such "inverting uncertainty intervals" approach of [19] allows us to easily incorporate our seroprevalence adjustments coming from a frequentist unnivariate imputation model into a Bayesian evidence synthesis model.

When it comes to the cumulative number of deaths D_k by cross-section k an obvious question is what date to use to compute this figure for each study cross-section. [29] suggest compute the total number of deaths up until seven days after the cross-section mid-point. [19] propose to treat D_k as an interval censored variable where we do not know its true value but observe its lower and upper bounds D_k^{lower} and D_k^{upper} for each cross-section. The authors define $D_k^{lower/upper}$ as the total number of deaths from the pandemic onset until 14 days after the start/the end of the cross-section k, respectively. We adopt this approach as it allows for uncertainty in the actual death counts.

Another concern is reliability of the reported deaths data. We use two sources for $D_k^{lower/upper}$. The first is the official national government website (stopcoronavirus.rf) that provides daily data on COVID-related deaths in St. Petersburg. The second is excess deaths estimation based on monthly data from the Federal State Statistics Service of Russia [11]. We find it valuable to compute the IFR and IR using the data from both sources given the voiced concerns about under-reporting of COVID-related deaths in the country. For monthly excess deaths data we consider the cumulative excess deaths from January 1, 2020 to the month of the cross-section start to define D_k^{lower} and the cumulative excess deaths from January 1, 2020 to the month of the cross-section end to define D_k^{upper} . All the variables used in the estimation are reported in Table S1.

Table S1. Data used for IR/IFR estimation in the Bayesian evidence synthesis model

k (cross-section dates)	P_k^{adult}	P_k^{all}	$T_k^{effective}$	$CC_k^{effective}$	$D_{k,official}^{lower}$	$D_{k,official}^{upper}$	$D_{k,excess}^{lower}$	$D_{k,excess}^{upper}$
1 (2020-05-25 – 2020-06-28)	4 451 025	5 398 064	827	79	392	1603	2978	4776
2 (2020-07-20 – 2020-08-08)	4 451 025	5 398 064	385	50	2062	2421	5949	6537
3 (2020-10-12 – 2020-12-06)	4 439 897	5 384 342	999	228	3627	6840	9045	14468
4 (2020-02-15 – 2020-04-04)	4 439 897	5 384 342	550	241	11112	12811	18944	21426

Results The per-cross-section estimates of IR/IFR under different priors and death intervals are reported in Table S2.

Per-age and sex IR and IFR Our approach can be easily applied to another problem. Suppose now that k indexes sex and age groups within one serosurvey cross-section. Then we can use the same logic to estimate IR and IFR for each age group-sex combinations.

We predict ELISA Coronapass-based seroprevalence within each sex and age group combination from our baseline univariate

Table S2. Estimated IR/IFR across the study cross-sections from the Bayesian evidence synthesis model

population		only adult population												
priors		weakly info	rmative			non-infor	weakly inform.							
estimate	I	R	IF	7R	I	R	IF	R	IR	IFR				
deaths	official	excess	official excess		official	official excess		official excess		ess				
1	9.28	9.22	0.29	1.01	9.41	9.30	0.27	1.01	9.22	0.83				
	(7.26-11.26)	(7.54-10.97)	(0.10-0.42)	(0.75-1.22)	(7.45-11.45)	(7.53-11.02)	(0.09-0.41)	(0.74-1.21)	(7.50-10.94)	(0.62-1.00)				
2	12.73	13.30	0.40	1.05	12.91	13.35	0.39	1.05	13.28	0.87				
	(9.64-16.03)	(10.72-15.72)	(0.29-0.51)	(0.87-1.28)	(9.80-16.33)	(10.81-15.83)	(0.29-0.51)	(0.86-1.27)	(10.73-15.75)	(0.71-1.05)				
3	22.78	22.84	0.48	1.05	22.82	22.87	0.48	1.06	22.84	0.87				
	(20.26-25.41)	(20-41-25-39)	(0.34-0.66)	(0.87-1.33)	(20.25-25.40)	(20-42-25-43)	(0.34-0.67)	(0.87-1.34)	(20-40-25-41)	(0.72-1.10)				
4	43.84	43.64	0.61	1.04	43.80	43.65	0.61	1.04	43.64	0.86				
	(39.85-48.09)	(39.75-47.53)	(0.54-0.69)	(0.93-1.16)	(39.63-47.83)	(39.63-47.54)	(0.54-0.69)	(0.93-1.16)	(39.68-47.47)	(0.77-0.96)				
Overall	8.69	8.74	0.43	1.04	23.38	23.29	0.50	1.04	8.79	0.86				
	(0.85–17.77)	(1.05–18.09)	(0.11-0.82)	(0.80-1.31)	(4.25–63.35)	(4.53–63.94)	(0.04–19.63)	(0.80-1.35)	(0.91-18.07)	(0.66-1.08)				

model for cross-section 4 where we use an interaction between individual age group and sex instead of treating them as linearly separable variables (as reported in Table S8) and define more fine-grained age groups. Then we invert the estimated CI for the seroprevalence to compute the $T_k^{effective}$ and $CC_k^{effective}$ (see Table S3). For per-group population P_k we use data as of the beginning of 2020 since no data for 2021 is available yet.

When it comes to D_k^{lower} and D_k^{upper} we need to acknowledge that, to the best of our knowledge, no official data on deaths from COVID-19 disaggregated by age and sex exists. For this reason, we rely on excess deaths data estimation. We gather official yearly data on deaths in 2016–19 by age group and sex and quarterly data on deaths in 2020–21 to compute our $D_{k,excess}^{lower/upper}$. We used quarterly data of age and sex-specific number of deaths and population from the Federal State Statistics Service of Russia. First, we combined the number of deaths from all causes from the second, third, and fourth quarter of 2020, and the first quarter of 2021 (the pandemic year). We treated the pandemic year as a calendar year, as it captures all seasonal trends, and includes all periods when excess deaths due to COVID-19 are expected. The first case of SARS-CoV-2 infection was registered in Saint Petersburg in Russia on March 5, 2020, and it is not likely that the first quarter of 2020 contributed to excess mortality due to COVID-19. We estimated expected deaths by using a Poisson model that accounts for annual temporal trends within each age and sex-specific group with an offset that accounts for the population size in each group. For each age and sex-specific group, the model used mortality data for 2016-19 to estimate the expected number of deaths in each group for 2020. Then the predicted lower and upper bound for expected death count in 2020 was used to estimate the number of excess death in the pandemic year. The cumulative number of deaths across all age and sex-specific groups combined (the lower bound was 18 631 and the upper was 22 289) was in line with the excess deaths estimation based on monthly data from the Federal State Statistics Service of Russia (the lower bound was 18 944 and the upper 21 426) [11].

The estimated IR and IFR for each age and sex-specific group combination are in Table S4.

Table S3. Data used for IR/IFR estimation for cross-section 4 (ELISA Coronapass) in the Bayesian evidence synthesis model by age group and sex

Sex	Age group	P_k^{group}	Seroprevalence	$T_k^{effective}$	$CC_k^{effective}$	$D_{k,excess}^{lower}$	$D_{k,excess}^{upper}$
Female	18–29	419 516	40.2 (31.3–49.2)	115	46	0	36
Female	30–39	543 892	44.6 (38.2–50.9)	234	104	57	182
Female	40–49	432 308	50.2 (41.7–58.7)	131	66	167	341
Female	50-59	418 371	49.2 (40.4–58.0)	122	60	367	596
Female	60–69	437 588	34.4 (22.0–46.8)	54	18	1412	1755
Female	70+	482 856	37.4 (17.6–57.3)	20	7	7679	8509
Male	18–29	413 098	44.6 (32.8–56.4)	65	29	0	105
Male	30–39	527 930	61.5 (52.4–70.7)	105	65	161	352
Male	40–49	404 853	54.1 (43.1–65.0)	79	43	528	791
Male	50-59	342 243	63.5 (49.9–77.1)	45	29	856	1167
Male	60–69	281 789	56.5 (36.4–76.6)	21	12	2111	2527
Male	70+	241 605	33.6 (1.3–65.9)	5	1	5330	5928

Table S4. Estimated IR/IFR across the age and sex groups from the Bayesian evidence synthesis model, cross-section 4, ELISA Coronapass

priors		weakly info	ormative		non-informative					
estimate	I	IR		FR	I	R	IFR			
sex	female	male	female	female male		male	female	male		
18–29	40.04	43.54	0.01	0.02	42.32	45.84	0.01	0.02		
30–39	(31·86–48·73) 44·11	(32·67–54·11) 58·57	0.00-0.02 0.05	(0·00–0·06) 0·08	(34·10–50·11) 45·06	(36·07–55·33) 57·66	(0·00–0·02) 0·05	(0·00–0·05) 0·08		
	(38·13–50·09)	(49·22–68·27)	(0.02-0.08)	(0.05-0.12)	(39·11–50·84)	(48-45-67-11)	(0.02-0.08)	(0.05-0.12)		
40–49	49.00	51.63	0.11	0.31	49.57	51.86	0.11	0.31		
50–59	(41·32–57·24) 47·96	(41·64–62·02) 57·75	(0.07-0.17) 0.23	(0·22–0·41) 0·51	(42·32–57·28) 48·72	(42·88–61·42) 56·39	(0.07-0.16) 0.23	(0.22-0.40) 0.52		
20 27	(39.97–56.22)	(44·79–71·93)	(0.17-0.32)	(0.37–0.67)	(41·23–56·51)	(45.67–69.94)	(0.16-0.31)	(0.38-0.68)		
60–69	36.09	49.91	1.00	1.64	40.65	51.11	0.89	1.60		
70+	(24·80–47·93) 39·22 (22·50–53·98)	(34·01–67·33) 38·37 (15·91–57·49)	(0.70-1.43) 4.27 $(2.76-6.73)$	(1·13–2·30) 6·06 (3·47–12·37)	(29·54–50·86) 44·68 (30·09–56·77)	(38·40–66·05) 45·91 (28·86–61·22)	(0.65-1.20) 3.75 $(2.77-5.23)$	(1·17–2·09) 5·07 (3·51–7·49)		

Table S5. Summary statistics across study cross-sections

cross-section dates	2020-05-25 - 202			6-28	2020-	07-20 - 2020-08-08	2020 - 10 - 12 - 2020 - 12 - 06				2020-02-15 - 2020-04-04	
subsample	interv	iewed	ed tested		tested		interviewed		tested		tested**	
statistic	N	Mean	N	Mean	N	Mean	N	Mean	N	Mean	N	Mean
Male	6,400	0.412	1,038	0.372	497	0.374	7,718	0.424	1,391	0.341	1,185	0.339
Age group 18–34	6,400	0.365	1,038	0.382	497	0.356	7,718	0.331	1,391	0.369	1,185	0.341
Age group 35–49	6,400	0.318	1,038	0.344	497	0.332	7,718	0.318	1,391	0.361	1,185	0.372
Age group 50–64	6,400	0.199	1,038	0.210	497	0.249	7,718	0.207	1,391	0.206	1,185	0.229
Age group 65+	6,400	0.119	1,038	0.065	497	0.062	7,718	0.144	1,391	0.064	1,185	0.058
Higher education	6,400	0.671	1,038	0.828	497	0.853	7,718	0.619	1,391	0.797	1,185	0.824
Higher income	6,063	0.425	999	0.504	480	0.533	6,930	0.365	1,303	0.424	1,118	0.442
Respondent lives alone	6,400	0.187	1,038	0.188	497	0.217	7,718	0.191	1,391	0.171	1,185	0.169
Started to wash hands more often since pandemic	6,345	0.655	1,033	0.712	493	0.728	7,637	0.634	1,388	0.705	1,180	0.709
History of illness in the last 3 months	6,321	0.316	1,031	0.440	496	0.435	7,185	0.564	1,337	0.690	1,143	0.721
History of COVID-19 testing	6,400	0.152	1,038	0.225	497	0.243	7,718	0.360	1,391	0.447	1,143	0.721
Current smoker*	_	_	949	0.205	450	0.182	7,718	0.315	1,391	0.254	_	_
Encouraged to participate in study	6,400	0.231	1,038	0.232	497	1.000	7,718	0.517	1,391	0.566	1,185	0.000
CMIA Abbott positive	_	_	1,038	0.093	497	0.139	_	_	1,390	0.164	_	_
ELISA Genetico positive	_	_	1,035	0.103	495	0.147	_	_	1,378	0.227	1,182	0.532
ELISA Vector positive	_	_	_	_	_	_	1,348	0.247	1,348	0.247	1,169	0.546

^{*—}current smoking status variable is gathered from the paper-based survey of tested individuals in the clinic during the first cross-section and is extrapolated for the same individuals for the second cross-section. For the third cross-section all individuals were asked about their smoking status during the phone interview. **— for the purposes of the analysis we excluded vaccinated individuals from the tested subsample of individuals in the fourth cross-section, assumed that they failed to agree to get tested, and used their predicted seropositivity status from our univariate imputation model rather than the actual test results.

Table S6. Representativeness of the survey across study cross-sections

	Interviewed, 2020-05-25 – 2020-06-28	Interviewed, 2020-10-12 – 2020-12-06	KOUZh-2018
Male, %	41.2	42.5	40.2
	(40·0–42·4)	(41·4–43·6)	(38-4-41-9)
Age, years	43.0	44.1	46.7
	(42·7–43·4)	(43·8–44·5)	(46·1-47·3)
18-34, %	36·3	33.4	27.9
	(35·1–37·5)	(32·3–34·5)	(26·3–29·5)
35-49, %	31.8	31.9	31.7
	(30·7–32·9)	(30.9–33.0)	(30.0-33.3)
50-64, %	19-9	20.6	22.8
	(19·0–20·9)	(19·7–21·5)	(21·3–24·3)
65+, %	11.9	14·1	17.6
	(11·1–12·7)	(13·3–14·9)	$(16 \cdot 3 - 19 \cdot 0)$
Education			
Primary / secondary education, %	10.0	10.5	12.9
	(9·2–10·7)	(9·8–11·2)	(11.7-14.1)
Special secondary education, %	23.0	27.4	39.5
	(22·0–24·1)	(26·4–28·4)	(37.7-41.3)
Higher education, %	67.0	62.0	47.6
	(65·9–68·2)	(60.9–63.1)	(45·8–49·4)
Employed, %	68·3	65.0	70.2
	(67·1–69·4)	(64·0–66·1)	(68·6–71·8)
Current smoker*, %	20.5	31.5	31.6
	(18·0–23·1)	(30·5–32·6)	(30.0-33.3)
Self-reported health status			
Very good, %	19.9	16.2	7.8
	(18·9–20·9)	(15·4–17·0)	(6.8-8.7)
Good, %	48.9	48.6	45.3
	(47·7–50·1)	(47·5–49·7)	(43.5–47.1)
Satisfactory, %	28.5	32.3	39.2
	(27·4–29·6)	(31·2–33·3)	(37·5–41)
Bad, %	2.4	2.4	7.1
	(2·0–2·8)	(2·0–2·7)	$(6 \cdot 2 - 8 \cdot 0)$
Very bad, %	0.3	0.5	0.6
	(0.2–0.5)	(0.4–0.7)	(0.3-0.9)
Lives alone, %	18:7	19.1	19.7
	(17-7–19-6)	(18·2–19·9)	(18·3–21·1)
Has cellphone, %	100	100	99.5
			(99·3–99·8)
N	6336	7595	2977

95% confidence intervals in parentheses. "Interviewed" means individuals who agreed to participate in the respective cross-section of the phone survey. KOUZh-2018 is the 2016 round of the Comprehensive Monitoring of Living Conditions household survey carried out by the Federal State Statistics Service of Russia. We subset this survey to include only adults in St. Petersburg. We report only complete-case observations in terms of all variables, therefore the number of observations is slightly lower due to listwise deletion. * — current smoking status variable is gathered from the paper-based survey of tested individuals in the clinic during cross-section 1 (N = 949).

Figure S1. Naïve and adjusted seroprevalence by study cross-section and week (ELISA Coronapass)




Table S7. Seroprevalence by cross-section: naïve adjusted for non-response bias or adjusted for non-response and test performance

test		CMIA	Abbott			ELISA C	oronapass		ELISA Vector				
estimate	naïve	naïve	adjusted	adjusted	naïve	naïve	adjusted	adjusted	naïve	naïve	adjusted	adjusted	
raking	no	yes	no	yes	no	yes	no	yes	no	yes	no	yes	
2020-10-12 - 2020-12-06	14.2	14.3	11.5	11.2	11.6	11.6	9.7	9.4	_	_	_	_	
2020-07-20 - 2020-08-08	(11·5–16·9) 21·1	(11·6–17·0) 19·7	(9·0–14·1) 16·1	(8·2–14·3) 14·0	(9·5–13·6) 16·5	(9·5–13·7) 15·5	(7·7–11·7) 13·3	(7·0–11·8) 11·4	_	_	_	_	
2020-10-12 - 2020-12-06	(16·5–25·7) 24·9	(15·2–24·3) 25·4	(11·8–20·4) 22·0	(9·3–18·6) 22·0	(13·0–20·0) 25·2	(12·0–18·9) 26·4	(9·9–16·6) 22·9	(7·9–15·0) 23·8	26.9	28.1	23.9	24.6	
2020-02-15 - 2020-04-04	(22·0–27·9)	(22·4–28·4)	(19·0–25·1)	(18·5–25·6)	(22·8–27·7) 57·9 (54·7–61·0)	(23·9–28·9) 56·5 (53·4–59·7)	(20·3–25·5) 43·9 (39·7–48·0)	(20·7–26·9) 42·1 (37·5–46·8)	(24·3–29·4) 58·2 (55·1–61·3)	(25·5–30·6) 57·1 (54·0–60·2)	(21·3–26·4) 49·5 (45·7–53·2)	(21·5–27·7) 48·6 (44·2–52·9)	

 Table S8.
 Seroprevalence by subgroup, ELISA Coronapass

		2020-	05-25 - 2020-06-28	2020-0	07-20 - 2020-08-08	2020-1	0-12 - 2020-12-06	2020-	02-15 - 2020-04-04
		N	seroprevalence	N	seroprevalence na	N ïve	seroprevalence	N	seroprevalence
Age group	18-34	387	13.8 (10.2–17.4)	172	16.4 (10.6–22.2)	499	24.4 (20.4–28.4)	391	51.7 (46.3–57.1)
	35-49	341	9.2 (6.0–12.5)	158	16.5 (10.4–22.6)	479	25.9 (21.7-30.0)	428	61.5 (56.4-66.6)
	50-64	199	13.7 (8.6–18.7)	116	20.6 (12.9-28.4)	267	28.1 (22.4-33.8)	257	65.1 (58.6–71.6)
	65+	61	3.6 (0.0-8.4)	28	_ ′	77	16.9 (8.1–25.7)	64	42.5 (29.5–55.5)
Female		623	11.0 (8.4–13.6)	300	16.7 (12.2–21.1)	874	23.9 (20.9–26.9)	747	54.0 (50.1–57.9)
Male		365	12.5 (8.9–16.1)	174	16.2 (10.5–22.0)	448	27.9 (23.5–32.3)	393	65.3 (60–70.5)
Higher education	no	168	13.6 (8.2–19.0)	68	12.8 (4.5–21.1)	261	28.3 (22.5–34.1)	200	48.9 (41.4–56.4)
<i>g</i>	yes	820	11.1 (8.9–13.4)	406	17.1 (13.3–21)	1061	24.5 (21.8–27.2)	940	59.8 (56.3–63.2)
Higher income	no	491	11.1 (8.2–14.0)	221	13.8 (9.0–18.5)	_		_	_
Tilgilet income	yes	497	12.0 (9.0–15.0)	253	18.9 (13.8–24.0)	_	_	_	
Respondent lives alone	no	803	12.5 (10.1–14.8)	372	18.4 (14.3–22.6)	1094	26 (23·3–28·8)	951	59.8 (56.3-63.2)
respondent nives dione	yes	185	7.6 (3.6–11.6)	102	9.6 (3.6–15.6)	228	21.5 (15.8–27.1)	189	48.3 (40.6–56.0)
History of COVID-19 testing	no	760	8.4 (6.4–10.5)	357	11.6 (8.1–15.0)	726	16.2 (13.4–19.0)	319	35.4 (29.8–41.0)
Thistory of Covid-17 testing	yes	228	21.9 (16.3–27.6)	117	31.6 (22.6–40.5)	596	36.3 (32.2–40.4)	821	66.6 (63–70.2)
Current smoker	no		21 7 (10 3-27 0)		31 0 (22 0-40 3)	982	27.2 (24.3–30.2)		00 0 (03-70 2)
Current smoker	yes		_	_		340	19.5 (15.1–23.9)		
History of illnesses in the past 3 months	no	547	5.2 (3.2–7.1)	266	9.8 (6.1–13.5)	407	11.8 (8.5–15.0)	319	35.4 (29.8–41.0)
Thistory of fillesses in the past 3 months	ves	441	19.5 (15.6–23.4)	208	25.1 (18.9–31.3)	915	31.2 (28.1–34.4)	821	66.6 (63.0–70.2)
Started to wash hands more often since pandemic	no	279	16.4 (11.8–20.9)	128	24.6 (16.7–32.5)	389			00.0 (03.0-70.5)
Started to wash hands more often since pandernic		709	9.7 (7.4–11.9)	346	13.5 (9.7–17.3)	933	26·0 (21·4–30·6) 24·9 (22·0–27·9)	_	_
	yes	709	9.7 (7.4–11.9)		red for non-response			_	
	10.24	207	12.1		•			201	41.5 (24.4.1.0)
Age group	18-34	387	12.1 (8.7–15.5)	172	14.0 (8.8–19.2)	499	23.2 (19.4–27.0)	391	41.5 (36.1–47.0)
	35-49	341	8.0 (5.1–10.8)	158	15.5 (9.7–21.3)	479	24.1 (20.2–28.1)	428	48.1 (42.4–53.8)
	50-64	199	11.6 (7.1–16.0)	116	15.5 (8.7–22.3)	267	25.0 (19.8–30.2)	257	50.4 (43.1–57.6)
	65+	61	3.3 (0.0–7.7)	28.0	_	77	15.9 (7.8–24)	64	29.5 (18.4–40.5)
Female		623	9.3 (7.0–11.7)	300	14.2 (10.2–18.2)	874	22.1 (19.1–25.1)	747	37.9 (33.4–42.4)
Male		365	10.2 (7.1–13.4)	174	11.9 (7.1–16.8)	448	23.9 (19.9–27.9)	393	52.0 (46.0–57.9)
Higher education	no	168	10.5 (6.2–14.7)	68	8.8 (2.7–14.8)	261	24.1 (19.0–29.2)	200	37.3 (30.2–44.4)
	yes	820	9.4 (7.3–11.4)	406	15.4 (11.6–19.2)	1061	22.1 (19.6–24.7)	940	47.5 (43.2–51.8)
Higher income	no	491	9.2 (6.6–11.8)	221	11.1 (7.1–15.2)		_	_	_
	yes	497	10.4 (7.6–13.2)	253	16.1 (11.2–20.9)	_	_	_	_
Respondent lives alone	no	803	10.6 (8.3–12.8)	372	14.6 (10.7–18.4)	1094	23.8 (21.0–26.6)	951	45.5 (41.0-49.9)
	yes	185	5.9 (2.6–9.2)	102	7-4 (2-6–12-2)	228	18.7 (13.8–23.7)	189	36.9 (29.8-44.0)
History of COVID-19 testing	no	760	7.7 (5.6–9.7)	357	10.2 (6.8–13.5)	726	15.2 (12.3–18.1)	319	34.3 (28.8–39.9)
	yes	228	20.9 (15.4–26.3)	117	30.2 (21.3-39.1)	596	36 (31.8-40.3)	821	66.5 (62.7–70.3)
Current smoker	no	_	_	_	_	982	24.8 (21.9–27.8)	_	_
	yes	_	_	_	_	340	18.5 (14.3-22.8)	_	_
History of illnesses in the past 3 months	no	547	5.4 (3.3–7.5)	266	9.0 (5.4–12.7)	407	11.7 (8.3–15.2)	319	39.6 (34.8-44.5)
*	yes	441	18.9 (14.9-22.8)	208	22.3 (16.3–28.2)	915	31.5 (28.1–34.9)	821	49.1 (45.7–52.6)
Started to wash hands more often since pandemic	no	279	12.7 (8.8–16.5)	128	19.2 (12.6-25.8)	389	24.0 (19.6-28.4)	_	_
1	yes	709	8.2 (6.1–10.3)	346	10.2 (6.9–13.5)	933	22.2 (19.3–25.1)		_